Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)

Francesco Oddone (Coresponding Author), James Kirwan, Fernando Lopez-Lopez, The VISIONARY Study Group, Guna Laganovska (Member of the Working Group)

Research output: Contribution to journalErratumpeer-review

6 Downloads (Pure)

Abstract

The authors would like to acknowledge missing data for all prior latanoprost users as a whole. The following sentence has been added to the manuscript (page 8, first paragraph): Mean (SD) reduction from baseline at Month 6 for users of all latanoprost formulations (preserved and PF) was 6.1 (4.25) mmHg (25.9%; p\0.0001). The authors have also prepared a table to summarise the change in intraocular pressure following a switch to the preservative-free tafluprost/timolol fixed-dose combination from all latanoprost formulations (preserved and preservative-free formulations). See Table 1 below.(Table Preseneted.) .The original article has been corrected.

Original languageEnglish
Pages (from-to)3522-3523
Number of pages2
JournalAdvances in Therapy
Volume39
Issue number8
DOIs
Publication statusPublished - Aug 2022
Externally publishedYes

Keywords*

  • Beta-blocker monotherapy
  • Ocular hypertension
  • Open-angle glaucoma
  • Preservative-free topical medication
  • Prostaglandin analogue monotherapy
  • Real-world evidence
  • Tafluprost/timolol fixed-dose combination
  • VISIONARY study

Field of Science*

  • 3.2 Clinical medicine

Publication Type*

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database

Fingerprint

Dive into the research topics of 'Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)'. Together they form a unique fingerprint.

Cite this